REL and diffuse large B-cell lymphoma: Consistent with their clinical and genetic (clonal) heterogeneity, several diverse genetic abnormalities have been identified in DLBCL including aberrant somatic hypermutations, nonrandom chromosomal deletions, balanced reciprocal translocations deregulating the expression of proto-oncogene products such as BCL6, REL, BCL2 or c-MYC, and often associated with dysregulated apoptosis or defective DNA repair [2, 3, 12, 13, 15–17].